INDP (Indaptus Therapeutics) Short Interest


INDP Indaptus Therapeutics Inc INDP
26 GF Score
Price $3.55
! 1 Warning Sign
View Full Analysis

What is Indaptus Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

INDP vs KPTI, NBP, IMUX: Short Interest Comparison

For the Biotechnology subindustry, Indaptus Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indaptus Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Indaptus Therapeutics's Short Interest falls into.


INDP
26GF Score
Indaptus Therapeutics Inc INDP
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indaptus Therapeutics Business Description

Address 3 Columbus Circle 15th Floor, New York, NY, USA, 10019
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
26GF Score

Get the complete analysis for INDP

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price